Home | Publications | Receptor activator of nuclear factor kappa-Β ligand (RANKL) serum levels are associated with progression to seropositive/negative rheumatoid arthritis

Receptor activator of nuclear factor kappa-Β ligand (RANKL) serum levels are associated with progression to seropositive/negative rheumatoid arthritis

Published on: 21 May, 2021

Burska A, El-Jawhari J, Wu J, Wakefield R, Marzo-Ortega H, Conaghan P, Emery P, Ponchel F, Freeston J. Receptor activator of nuclear factor kappa-Β ligand (RANKL) serum levels are associated with progression to seropositive/negative rheumatoid arthritis. Clin Exp Rheumatol. May-Jun 2021;39(3):456-462.

Link to Publication

Receptor activator of nuclear factor kappa-Β ligand (RANKL) serum levels are associated with progression to seropositive/negative rheumatoid arthritis

Published on: 21 May, 2021

Related Themes

Musculoskeletal

Related Team Members

Professor Paul Emery

Musculoskeletal Diseases Theme Lead